|AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.||Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.|
Cooperation with Cyclenium
AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives
AiCuris and Cyclenium announced today the signing of a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases.
AIC649 Positive Phase 1 Hepatitis B
AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B